Infect Chemother.
2024 Dec;56(4):453-460. 10.3947/ic.2024.0142.
COVID-19 Vaccination Recommendations for 2024–2025 in Korea
- Park WB
1 - Hwang YH1
- Kwon KT2
- Noh JY3
- Park SH4
- Song JY3
- Choo EJ5
- Choi MJ6
- Choi JY7
- Heo JY8
- Choi WS3
- the Committee on Adult Immunization of the Korean Society of Infectious Diseases
- Affiliations
-
- 1Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
- 2Division of Infectious Diseases, Department of Internal Medicine, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Korea
- 3Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea
- 4Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 5Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, Soonchunhyang University of Korea, Bucheon, Korea
- 6Division of Infectious Diseases, International St Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, Korea
- 7Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
- 8Department of Infectious Diseases, Ajou University School of Medicine, Suwon, Korea
- KMID: 2564024
- DOI: http://doi.org/10.3947/ic.2024.0142
Abstract
- The Korean Society of Infectious Diseases has been regularly publishing guidelines for adult immunization since 2007. Following the release of coronavirus disease 2019 (COVID-19) vaccination recommendations in 2023, significant changes have occurred due to the emergence of new variant strains and the waning immunity from previous vaccinations. This article provides a comprehensive update as of November 2024, incorporating the latest evidence and guidelines. Focusing on the 2024–2025 season, this article reviews vaccines currently authorized in Korea and assesses their effectiveness against the predominant JN.1 lineage variants. The updated recommendations prioritize high-risk groups, including adults aged 65 and older, individuals with underlying medical conditions, residents of facilities vulnerable to infection, pregnant women, and healthcare workers, for vaccination with updated vaccines targeting the JN.1 strain. Additionally, COVID-19 vaccination is available for all individuals aged 6 months and older. For most adults, a single-dose strategy is emphasized, while tailored schedules may be recommended for immunocompromised individuals. This update aims to optimize vaccination strategies in Korea to ensure comprehensive protection for high-risk populations.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The Role of COVID-19 Vaccination for Patients With Atherosclerotic Cardiovascular Disease in the Upcoming Endemic Era
- A Case of Aphthous Stomatitis in a Healthy Adult Following COVID-19 Vaccination: Clinical Reasoning
- Examination of Predicting Factors for COVID-19 Vaccination Behaviors of University Students Utilizing the Theory of Planned Behavior
- Factors Influencing the COVID-19 Vaccination Intentions in Nurses: Korea, February 2021
- Vestibular Neuritis after COVID-19 Vaccination
